Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Prothena
Biotech
BMS pays $95M to exercise Evotec, Prothena neuroscience options
BMS is paying Prothena $55 million for a global license to a clinical-phase Alzheimer’s therapy and handing Evotec $40 million for discovery programs.
Nick Paul Taylor
Jul 11, 2023 5:30am
Prothena teams with Walgreens to accelerate Alzheimer's trial
Apr 13, 2023 9:55am
Prothena touts early data for anti-amyloid Alzheimer's drug
Jul 26, 2021 1:19pm
Biogen's Aduhelm win opened up market frenzy in Alzheimer's
Jul 15, 2021 9:12am
Novo Nordisk pays Prothena $100M for ATTR drug
Jul 12, 2021 8:15am
Bristol Myers, Lilly pile into Alzheimer's rush
Jun 24, 2021 11:50am